Genotype distribution of aPTT hit SNPs in the Three-City Study control patients and in MARTHA VT patients
| . | Three-City Study . | MARTHA08 . | MARTHA10 . |
|---|---|---|---|
| rs2731672 (F12) | |||
| CC | 659 (59) | 599 (62) | 365 (64) |
| CT | 394 (36) | 322 (33) | 183 (32) |
| TT | 57 (5) | 51 (5) | 22 (4) |
| MAF (T) | 0.229 | 0.218 | 0.199 |
| P | .124* | ||
| rs9898 (HRG) | |||
| CC | 454 (41) | 386 (40) | 222 (40) |
| CT | 534 (48) | 453 (46) | 264 (47) |
| TT | 120 (11) | 133 (14) | 73 (13) |
| MAF (T) | 0.349 | 0.370 | 0.367 |
| P | .141 | ||
| rs710446 (KNG1) | |||
| TT | 383 (35) | 280 (29) | 173 (30) |
| TC | 545 (49) | 497 (51) | 280 (49) |
| CC | 182 (16) | 194 (20) | 117 (20) |
| MAF (C) | 0.409 | 0.455 | 0.451 |
| P | .00117 | ||
| . | Three-City Study . | MARTHA08 . | MARTHA10 . |
|---|---|---|---|
| rs2731672 (F12) | |||
| CC | 659 (59) | 599 (62) | 365 (64) |
| CT | 394 (36) | 322 (33) | 183 (32) |
| TT | 57 (5) | 51 (5) | 22 (4) |
| MAF (T) | 0.229 | 0.218 | 0.199 |
| P | .124* | ||
| rs9898 (HRG) | |||
| CC | 454 (41) | 386 (40) | 222 (40) |
| CT | 534 (48) | 453 (46) | 264 (47) |
| TT | 120 (11) | 133 (14) | 73 (13) |
| MAF (T) | 0.349 | 0.370 | 0.367 |
| P | .141 | ||
| rs710446 (KNG1) | |||
| TT | 383 (35) | 280 (29) | 173 (30) |
| TC | 545 (49) | 497 (51) | 280 (49) |
| CC | 182 (16) | 194 (20) | 117 (20) |
| MAF (C) | 0.409 | 0.455 | 0.451 |
| P | .00117 | ||
Values are n (%).
aPTT indicates activated partial thromboplastin time; MAF, minor allele frequency; MARTHA, MARseille THrombosis Association study; SNP, single nucleotide polymorphisms; VT, venous thrombosis.
P value of the Cochran-Armitage trend test.